This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagler, A. Articles by Vlodavsky, I. Search for Related Content PubMed PubMed Citation Articles by Nagler, A. Articles by Vlodavsky, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:194-202.)
© 1997 American Heart Association, Inc.

Articles

Inhibition of Collagen Synthesis, Smooth Muscle Cell Proliferation, and Injury-Induced Intimal Hyperplasia by Halofuginone

Arnon Nagler; Hua-Quan Miao; Helena Aingorn; Mark Pines; Olga Genina; Israel Vlodavsky

the Departments of Bone Marrow Transplantation (A.N.) and Oncology (H.-Q.M., H.E., I.V.), Hadassah-Hebrew University Hospital, Jerusalem, and the Institute of Animal Science (M.P., O.G.), Agricultural Research Organization, the Volcani Center, Bet Dagan, Israel.

Correspondence to Dr Israel Vlodavsky, Department of Oncology, Hadassah Hospital, PO Box 12 000, Jerusalem, 91120, Israel.

Proliferation of vascular smooth muscle cells (SMCs) and accumulation of extracellular matrix (ECM) components within the arterial wall in response to local injury are important etiologic factors in vascular proliferative disorders such as arteriosclerosis and restenosis after angioplasty. Fibrillar and nonfibrillar collagens are major constituents of the ECM that modulate cell shape and proliferative responses and thereby contribute to the pathogenesis of intimal hyperplasia. Halofuginone, an anticoccidial quinoazolinone derivative, inhibits collagen type I gene expression. We investigated the effect of halofuginone on (1) proliferation of bovine aortic endothelial cells and SMCs derived from the same specimen and maintained in vitro, (2) ECM deposition and collagen type I synthesis and gene expression, and (3) injury-induced intimal hyperplasia in vivo. DNA synthesis and proliferation of vascular SMCs in response to serum or basic fibroblast growth factor were abrogated in the presence of as little as 0.1 µg/mL halofuginone; this inhibition was reversible upon removal of the compound. Under the same conditions, halofuginone exerted a relatively small antiproliferative effect on the respective vascular endothelial cells. Halofuginone also inhibited the synthesis and deposition of ECM components by vascular SMCs as indicated both by a substantial reduction in the amount of sulfated proteoglycans and collagen type I synthesis and gene expression. Local administration of halofuginone in the rabbit ear model of crush injury–induced arterial intimal hyperplasia resulted in a 50% reduction in intimal thickening as measured by a morphometric analysis of the neointima/media ratio. The differential inhibitory effect of halofuginone on vascular SMCs versus endothelial cells, its inhibition of ECM deposition and collagen type I synthesis, and its ability to attenuate injury-induced intimal hyperplasia may place halofuginone alone or in combination with other antiproliferative compounds as a potential candidate for prevention of arterial stenosis and accelerated atherosclerosis.

Key Words: vascular smooth muscle cell • intimal proliferation • extracellular matrix • fibroblast growth factor • collagen type I

This article has been cited by other articles:

				M. Leiba, L. Cahalon, A. Shimoni, O. Lider, A. Zanin-Zhorov, I. Hecht, U. Sela, I. Vlodavsky, and A. Nagler Halofuginone inhibits NF-{kappa}B and p38 MAPK in activated T cells J. Leukoc. Biol., August 1, 2006; 80(2): 399 - 406. [Abstract] [Full Text] [PDF]

				Y. Popov, E. Patsenker, M. Bauer, E. Niedobitek, A. Schulze-Krebs, and D. Schuppan Halofuginone Induces Matrix Metalloproteinases in Rat Hepatic Stellate Cells via Activation of p38 and NF{kappa}B J. Biol. Chem., June 2, 2006; 281(22): 15090 - 15098. [Abstract] [Full Text] [PDF]

				A. Segev, D. Aviezer, M. Safran, Z. Gross, and A. Yayon Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist Cardiovasc Res, January 1, 2002; 53(1): 232 - 241. [Abstract] [Full Text] [PDF]

				M. ELKIN, H.-Q. MIAO, A. NAGLER, E. AINGORN, R. REICH, I. HEMO, H.-L. DOU, M. PINES, and I. VLODAVSKY Halofuginone: a potent inhibitor of critical steps in angiogenesis progression FASEB J, December 1, 2000; 14(15): 2477 - 2485. [Abstract] [Full Text]

				M. Elkin, I. Ariel, H.-Q. Miao, A. Nagler, M. Pines, N. de-Groot, A. Hochberg, and I. Vlodavsky Inhibition of Bladder Carcinoma Angiogenesis, Stromal Support, and Tumor Growth by Halofuginone Cancer Res., August 1, 1999; 59(16): 4111 - 4118. [Abstract] [Full Text] [PDF]

				M. Elkin, R. Reich, A. Nagler, E. Aingorn, M. Pines, N. de-Groot, A. Hochberg, and I. Vlodavsky Inhibition of Matrix Metalloproteinase-2 Expression and Bladder Carcinoma Metastasis by Halofuginone Clin. Cancer Res., August 1, 1999; 5(8): 1982 - 1988. [Abstract] [Full Text] [PDF]

				Y. Numaguchi, K. Naruse, M. Harada, H. Osanai, S. Mokuno, K. Murase, H. Matsui, Y. Toki, T. Ito, K. Okumura, et al. Prostacyclin Synthase Gene Transfer Accelerates Reendothelialization and Inhibits Neointimal Formation in Rat Carotid Arteries After Balloon Injury Arterioscler Thromb Vasc Biol, March 1, 1999; 19(3): 727 - 733. [Abstract] [Full Text] [PDF]

				M. D. Rekhter Collagen synthesis in atherosclerosis: too much and not enough Cardiovasc Res, February 1, 1999; 41(2): 376 - 384. [Abstract] [Full Text] [PDF]